Seattle, United States
Parse Biosciences, founded in 2018 and headquartered in the United States, is a dynamic player in the Biotechnology and Life Sciences sectors. With a compelling slogan—"Scalable Single Cell Sequencing Without the Instrument"—the company is focused on revolutionizing single cell sequencing. Its innovative technology empowers researchers to advance in critical areas like cancer treatment, tissue repair, stem cell therapy, and understanding complex systems such as the immune system.
The company's value proposition lies in its ability to perform single cell sequencing with unprecedented scale and ease, a proposition that is attracting attention and investment. This global life sciences company recently received a substantial investment of $225.00M through an acquisition by Qiagen on 01 November 2025. These resources are likely to fuel further innovations and consolidate Parse Biosciences' pioneering role in facilitating groundbreaking discoveries within scientific research.
InVivo Biosystems
